


PHARMACEUTICAL 2020

Vistagen Therapeutics Inc. Rank 311 of 358











Vistagen Therapeutics Inc. Rank 311 of 358

The relative strengths and weaknesses of Vistagen Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vistagen Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 19% points. The greatest weakness of Vistagen Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 138% points.

The company's Economic Capital Ratio, given in the ranking table, is -119%, being 155% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	13,651
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,801
Liabilities, Non-Current	4,136
Other Assets	48
Other Compr. Net Income	0
Other Expenses	11
Other Liabilities	0
Other Net Income	-23
Other Revenues	0
Property and Equipment	313
Research and Development	17,098
Selling, General and Administrative Expense	7,458

Output Variable	Value in 1000 USD
Assets	14,012
Liabilities	6,936
Expenses	24,567
Revenues	0
Stockholders Equity	7,075
Net Income	-24,590
Comprehensive Net Income	-24,590
Economic Capital Ratio	-119%

